ng-nitroarginine methyl ester has been researched along with Diabetic Feet in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barinova, ME; Sulaieva, OM | 1 |
Fujii, T; Kuwano, H; Onimaru, M; Sueishi, K; Yonemitsu, Y | 1 |
2 other study(ies) available for ng-nitroarginine methyl ester and Diabetic Feet
Article | Year |
---|---|
[State of intracellular signaling systems in endothelial dysfunction].
Topics: Adrenergic alpha-Agonists; Adult; Aged; Arginine; Clonidine; Diabetic Foot; Endothelium, Vascular; Female; Humans; Male; Middle Aged; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Platelet Aggregation; Receptors, Adrenergic; Signal Transduction | 2007 |
Statins restore ischemic limb blood flow in diabetic microangiopathy via eNOS/NO upregulation but not via PDGF-BB expression.
Topics: Animals; Becaplermin; Blood Glucose; Cells, Cultured; Cholesterol, LDL; Combined Modality Therapy; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Foot; Enzyme Inhibitors; Genetic Therapy; Glycation End Products, Advanced; Hindlimb; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Muscle, Skeletal; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Platelet-Derived Growth Factor; Pravastatin; Proto-Oncogene Proteins c-sis; Quinolines; Regional Blood Flow; Signal Transduction; Time Factors; Up-Regulation | 2008 |